MIT Technology Review reports on the new male hormonal contraceptive gel developed by the Population Council in collaboration with the National Institute of Child Health and Human Development (NICHD) advancing to Phase II clinical trials.
The combination Nestorone® and Testosterone gel, a novel reversible contraceptive for men that is designed to be absorbed through the skin with minimal side effects, will enter a Phase II clinical trial in early 2018. The trial test the safety, efficacy, and acceptability of the new gel in preventing pregnancy among more than 400 couples in six countries. The new male contraceptive gel represents one of the Council’s many novel contraceptive and multipurpose prevention technologies to improve sexual and reproductive health in development at the Center for Biomedical Research (CBR).
Dr. Régine Sitruk-Ware, Distinguished Scientist at CBR and principal investigator of the trial spoke with MIT Technology Review about the male contraceptive gel and the importance of developing new contraceptive options to expand choices available to both men and women.
“Researchers like Sitruk-Ware think views are changing, and that men, especially younger men, will be open to using a contraceptive drug. ‘This is about gender equity,’ she says. ‘Men would also like to be able to regulate their own fertility and not be forced into fatherhood.’”